JPMorgan Chase & Co. Buys 38,626 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

JPMorgan Chase & Co. grew its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 172.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,977 shares of the company's stock after buying an additional 38,626 shares during the period. JPMorgan Chase & Co. owned 0.07% of NewAmsterdam Pharma worth $1,567,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $80,000. KLP Kapitalforvaltning AS purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth about $154,000. Barclays PLC raised its holdings in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after buying an additional 7,199 shares in the last quarter. HB Wealth Management LLC purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $224,000. Finally, Keybank National Association OH bought a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at $257,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Up 3.8 %

Shares of NASDAQ NAMS traded up $0.72 during trading on Thursday, reaching $19.85. The company had a trading volume of 136,261 shares, compared to its average volume of 596,078. The business's 50-day moving average is $19.58 and its 200 day moving average is $21.21. The stock has a market cap of $2.18 billion, a PE ratio of -7.63 and a beta of -0.01. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

NAMS has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma has an average rating of "Buy" and an average price target of $43.33.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 4,005 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now directly owns 3,012,434 shares of the company's stock, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.